- The coronovirus variant first found in Brazil, P.1, is still mutating, Brazil’s top public health body said.
- Some of these mutations may make the shot more resistant to vaccines, Firokruz said.
- Another study published on Wednesday indicated that P. 1 can curb those who were previously COVID-19s.
- For more articles, go to www.BusinessInsider.co.za.
P.1 Coronavirus version Due to the soaring cases in Brazil, Canada, and elsewhere The mutation is occurring in “particularly worrisome” ways that may make it more resistant to vaccines, researchers at Brazil’s major public health body have warned.
The variant is also able to rein in people who have already caught coronavirus, A new study published on Wednesday suggested.
Felipe Nevka, a researcher at the public-health body FiroCruz, said the new mutation affected a part of the virus that binds to cells, called spike proteins, and could create vaccines that would make this protein less effective. Huh, Per Reuters.
“We believe that this is another escape mechanism that viruses are creating to avoid a reaction to antibodies,” Naveka said. He works in the Amazon city of Manaus, where the P1 version is thought to have originated in December.
“This is particularly worrying as the virus continues to accelerate its development,” he said.
Naveka stated that the new changes were similar to the mutations first seen in variants found in South Africa, called B.1.151. In preliminary laboratory tests, Antibodies produced by Pfizer-BioNTech and Moderna’s COVID-19 vaccines Could not attach as well To B.1.351 compared to the original coronavirus.
In a separate, new study published on Wednesday, researchers said that compared with protection from previous virus infections, from COVID-19 infections, offering between 54% and 79% protection against future P.1 infections from previous coronavirus infections Was done. The study was conducted by University of Sao Paulo, Imperial College London, and Oxford University.
Public Health Agency in Canada, where P.1 cases have increased in recent weeks, On Thursday, the statement said Initial evidence suggested that the P.1 version may reduce the vaccine’s effectiveness, “making it even more important to control its spread.”
P.1 is twice as contagious as the original virus and has spread to 36 countries, According to the Global Initiative on Sharing All Influenza Data (GISAID). Only 500 cases have been registered in 31 states of the US Centers for Disease Control and Prevention (CDC).
Countries in which it predominates, p. 1 is infecting a greater number of young people. Brazilian hospital data show that in March more than half of all patients in intensive care were 40 or younger, Per Reuters.
Scientist Esther Sabino at the Faculty of Medicine of the University of São Paulo told Reuters that further mutations of the p.1 variant were not surprising given the rapid pace of transmission.
“If you have a high level of transmission, such as you currently have in Brazil, your risk of new mutations and mutations increases,” she said.